RISS 검색 - 국내학술지논문 상세보기

다국어 초록 (Multilingual Abstract)

Background: Endothelial dysfunction has been documented in patients with type 2 diabetes especially when combined with hypertension. We prospectively investigated the effects of pioglitazone in improving endothelial function in hypertensive type 2 diabetic patients during the 6-month follow-up. Methods: Hypertensive type 2 diabetic patients were randomly assigned to pioglitazone (n = 25) or placebo (n = 25). Primary endpoint was to compare changes in brachial artery flow-mediated dilation (baFMD) between the 2 groups during the 6-month follow-up. Secondary endpoints were to compare changes in the circulating levels of microRNA-17, -21, 92a, -126, and -145 which have been known as indicators of endothelial cell migration and atherosclerosis progression during the 6-month follow-up. Inflammatory markers such as interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high-sensitive C-reactive protein, adiponectin, soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cell adhesion molecule-1 (sVCAM-1) were compared during the follow-up. Results: The prevalences of risk factors such as hyperlipidemia, smoking, stroke, and family history of coronary artery disease did not show significant differences between the 2 groups. Increases in baFMD (0.33 ± 0.34 mm vs. 0.02 ± 0.25 mm, p ＜0.05, respectively) and in the level of circulating microRNA-21 (0.23 ± 0.05 vs. -0.06 ± 0.04, p ＜0.05, respectively) were significantly greater in the pioglitazone group when compared to the placebo group during the 6-month follow-up. No significant differences in the prevalences of new onset heart failure, fracture, and bladder cancer were noted during the follow-up between the 2 groups. Decreases in the levels of inflammatory marker such as IL-6 (-2.54 ± 2.32 pg/mL vs. -1.34 ± 2.12 pg/mL, p ＜ 0.05, respectively), TNF-α (-1.54 ± 1.51 pg/mL vs. 0.14 ± 1.12 pg/mL, p ＜ 0.05, respectively), sICAM-1 (-39 ± 52 ng/mL vs. 6 ± 72 ng/mL, p ＜0.05, respectively), and sVCAM-1 (-154 ± 198 ng/mL vs. -11 ± 356 ng/mL, p ＜ 0.05, respectively) were significantly greater in the pioglitazone group compared to the placebo group during the follow-up. Conclusions: In hypertensive type 2 diabetic patients, pioglitazone may increase baFMD and circulatory microRNA-21 and decrease inflammatory cytokines including IL-6, TNF-α, sICAM-1, and sVCAM-1.

번역하기

참고문헌 (Reference)

1 진동규, "당뇨가 있는 고혈압 환자에서 목표 혈압을 얼마까지 할 것인가?" 대한고혈압학회 17 (17): 10-16, 2011

2 유성혜, "The Effects of Pioglitazone in Reducing Atherosclerosis Progression and Neointima Volume in Type 2 Diabetic Patients: Prospective Randomized Study With Volumetric Intravascular Ultrasonography Analysis" 대한심장학회 40 (40): 625-631, 2010

3 Hong SJ, "Telmisartan reduces neointima volume and pulse wave velocity 8 months after zotarolimus-eluting stent implantation in hypertensive type 2 diabetic patients" 97 : 1425-1432, 2011

4 Maachi M, "Systemic low-grade inflammation is related to both circulating and adipose tissue TNF alpha, leptin and IL-6 levels in obese women" 28 : 993-997, 2004

5 Aubert RE, "Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes" 12 : 716-721, 2010

6 Hsiao FY, "Risk of bladder cancer in diabetic patients treated with rosiglitazone or pioglitazone : a nested case-control study" 36 : 643-649, 2013

7 Mizoguchi M, "Pioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aorta" 4 : 1110-1118, 2011

8 Ferwana M, "Pioglitazone and risk of bladder cancer : a meta-analysis of controlled studies" 30 : 1026-1032, 2013

9 Cheng Y, "MicroRNA-21 in cardiovascular disease" 3 : 251-255, 2010

10 Jazbutyte V, "MicroRNA-21 : from cancer to cardiovascular disease" 11 : 926-935, 2010